Effects of IGF-I in HIV Metabolic Disease

Status Terminated

Clinical Trial Summary

This study examines the effects of recombinant insulin like growth factor - I on body composition, glucose homeostasis, and lipids, in adults with HIV infection and signs of metabolic disease.

Clinical Trial Description

The main objectives of this study are the following:

1. Determine the effect of recombinant human insulin like growth factor-I (rhIGF-I) (generic: mecasermin) on subcutaneous adiposity in patients with HIV lipodystrophy syndrome.

2. Determine the effects of rhIGF-I on glucose homeostasis and lipids in patients with HIV lipodystrophy.

3. Determine the effects of rhIGF-I on apoptosis, mitochondria, and inflammation, in adipose tissue obtained from patients with HIV lipodystrophy. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01329744
Study type	Interventional
Source	University of Texas Southwestern Medical Center
Contact
Status	Terminated
Phase	Phase 1
Start date	June 2011
Completion date	June 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00656851` - Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome	N/A
Completed	`NCT03039491` - Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults	Early Phase 1
Recruiting	`NCT04904406` - Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals	Phase 4
Completed	`NCT00627380` - Yoga for the Management of HIV-Metabolic Syndromes	Phase 4
Completed	`NCT00795210` - Effects of Short-term Growth Hormone in HIV-infected Patients	N/A
Completed	`NCT01511016` - Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome	N/A
Recruiting	`NCT04903847` - Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil	Phase 4
Completed	`NCT01263717` - Effects of Growth Hormone Releasing Hormone in HIV	N/A
Completed	`NCT00362440` - Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome	Phase 2
Completed	`NCT05383456` - The Visceral Adiposity Measurement and Observation Study